Truist remains bullish on Edgewise Therapeutics’ EDG-7500 opportunity

Truist keeps a Buy rating and $46 price target on Edgewise Therapeutics (EWTX) following the company’s updates from Phase 2 EDG-7500 trial in Hypertrophic Cardiomyopathy, or HCM. Edgewise reported data from both 25mg dose as well as interim data from part D of the study, and the firm remains bullish of the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst tells investors in a research note.